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 2011 2012 2013 2014 
Radiation Oncologist 59% 18% 6% 4% 
Medical Physicists 4.5% 7% 2% 2% 
Dosimetrists - 5% - 7% 
Radiation Therapists 32% 70% 91% 87% 
Nurses 4.5% - - - 
Medical Secretary - - - 1% 
Nº of Events 22 44 120 112 
 
Dose errors were detected in 29 patients. In 9 patients 
afected more than 1 session (5 patients in 2011, 3 patients in 
2012, 1 patient in 2013 and no patients in 2014).  
The number of corrective actions has increased because of 
the increasing number of registered events: 2 in 2011, 4 in 
2012, 7 in 2013 and 9 in 2014. 
 
Conclusion: Event reporting and learning systems in 
radiotherapy can provide valuable data for patient safety 
treatment. An open acces event reporting improved 
identification of areas which needed process and safety 
improvements. The major indication of the effectiveness is 
the reduction in dose errors. 
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Purpose or Objective: Reference dosimetry audit 
measurements in UK radiotherapy centres have been carried 
out over the last 20 years. This work examines the variation 
in local dosimetry calibration in a network of radiotherapy 
centres, draws conclusions on the implementation of an 
absorbed dose based protocol for MV photon beams and 
includes the measured effect of a change in the nationally 
recommended electron code of practice (CoP) from an air 
kerma based to an absorbed dose based protocol. 
 
Material and Methods: Data from reference dosimetry audits 
conducted in radiotherapy centres by the National 
Measurement Institute (NMI) for photon, electron and kV x-
rays have been collated, recording the NMI:Centre ratio for 
reference output measurements, beam quality, and field 
chamber comparison. A total of 81 MV photon, 98 electron 
and 30 kV photon beams were measured during 68 visits 
between June 1994 and February 2015. The change in the 
national standard deviation has been assessed over time, and 
differences due to the change between the two electron CoPs 
during this period has been quantified. The improvement in 
consistency for MV beams since the adoption of a CoP 
traceable to a primary standard of absorbed dose is assessed. 
 
Results: The mean NMI:Centre difference for radiation 
output calibration was less than 0.25% for all modalities. A 
total of 7 measurements were reported to be outside the +/-
2% tolerance.There was a statistically significant difference 
(p=0.008) in the mean result for the respective air kerma 
based electron CoP, +0.75% (n=14) with the absorbed dose 
based protocol giving +0.20% (n=84). 
The variation in MV results has decreased steadily over time 
(see Figure 1). The standard deviation has halved when 
comparing the first and last 20 results, being 0.85% (2000) 
and 0.35% (2015). This trend has also been noted within 
regional audit groups. A linear correlation was observed 
between the ‘NMI:Centre output ratio’ and the ‘NMI:Centre 
field chamber comparison ratio’. 
There has been no significant difference observed between 
regional audit and national audit for the measured 
NMI:Centre ratios, but some regions have had many more NMI 
audits than others, some having no beams audited for a 
particular modality, and others having more than 20. 
 
Conclusion: Data has been collated from 20 years of NMI 
reference dosimetry audits, and key trends and changes have 
been noted. The introduction of the 2003 absorbed dose-
based electron CoP has decreased the difference between 
NMI and centre measured outputs. The use of a single 
absorbed dose based MV CoP, introduced just prior to the 
start of these audits, has contributed to the improved 
consistency demonstrated in these results. This not only 
shows the impact of a rigorous traceability chain developed 
by close collaboration between NMI and end users but also 
demonstrates that the NMI audit programme is likely to be a 
contributing factor to this improvement in consistency in 
dosimetry nationally. 
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Purpose or Objective: In the DBCG HYPO trial a number of 
radiation therapy (RT) parameters were prospectively 
determined for each individual treatment plan. These 
parameters were reported to a database and analyzed to 
determine the plan quality in the trial. 
 
Material and Methods: Patients (pts) for breast-only RT after 
surgery for early node-negative breast cancer from 8 RT 
centre in 3 countries were included in the trial between May 
2009 and March 2014. They were randomized to either 40 
Gy/15 fx or 50 Gy/25 fx. A number of plan-quality 
parameters such as doses to CTV-breast and organs at risk 
were determined for each plan. The use of respiratory gating 
during treatment was reported. Definitions on compliance to 
protocol guidelines, as well as minor and major deviations 
(Table 1) were agreed upon before trial start. After closing 
the trial, the QA parameters were analyzed and scored. 
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Results: A total of 1847 pts (904 right-sided and 943 left-
sided) were treated with either 40 Gy/15 fx (912 pts) or 50 
Gy/25 fx (935 pts). 388 of the left-sided pts were treated 
with gated RT, and 440 without. No information about gating 
was available for the remaining 115 pts. Dmax(CTV) was less 
than 110% of the prescription dose in 99.4% of the plans. 
More than 2 cm3 of the CTV received 107-110% of the dose in 
1% of the hypo-fractionated plans. For the normo-
fractionated plans, this deviation was observed in 3.5% of the 
plans. For 92.3% of the hypo-fractionated plans, less than 2% 
of the CTV was covered with doses above 105%, whereas 3.9% 
and 3.5% of the plans had minor and major deviations, 
respectively. For 80.8% of the pts, the part of the CTV 
covered with at least 95% of the prescription dose was in 
compliance with the guidelines. Minor and major deviations 
were observed for 12.6% and 6.6% of the pts, respectively. By 
taking laterality into consideration, 90.8% of the right-sided 
pts were in compliance with the guidelines compared to only 
71.2% of the left-sided pts. For the left-sided pts with 
available information about gating, it was found that 87.4% 
and 59.3% of the pts treated with and without gated RT, 
respectively, were in compliance, thus indicating that 
shielding of the heart resulted in CTV under-dosage. This was 
supported by compliance to the protocol heart dose 
guidelines for 941 left-sided pts. Only one hypo-fractionated 
pt showed a major deviation in V35Gy and a minor deviation 
in V17Gy (data missing for one pt). The lung dose satisfied 
the protocol guidelines for 99.4% of the pts.  
 
Conclusion: A high degree of compliance with protocol 
guidelines was found for the DBCG HYPO trial. Only a few pts 
received CTV doses above 107% of the prescription dose. The 
CTV volume covered with less than 95% dose deviated from 
protocol guidelines for about 40% of the left-sided pts treated 
without gated RT. With gated RT this number decreased to 
about 12%, almost equal to that of right-sided pts. This 
indicates that gated RT for left-sided pts reduces the 
necessity of CTV dose compromise due to heart shielding. 
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Purpose or Objective: Stereotactic ablative radiotherapy 
(SABR) is routinely used for the treatment of early stage lung 
cancer and is increasingly used to treat other primary tumour 
sites. There are currently 6 UK studies (of which 3 are 
randomised) investigating the utility of SABR in the treatment 
of oligometastatic disease (breast, lung, prostate), lung, 
prostate, pancreas and hepatobiliary primary malignancies. 
These are supported by CRUK and currently open or in set-up 
to begin recruitment in 2016. In addition, a NHS 
Commissioning Through Evaluation (CTE) programme was 
commenced in 2015 to evaluate SABR in situations where 
clinical trials are not available. In an attempt to standardise 
protocols and the associated radiotherapy planning we sought 
to generate consensus normal tissue dose constraints 
tolerances across these UK studies. 
 
Material and Methods: Members of the various SABR studies' 
trial management groups, facilitated by the UK Radiotherapy 
Trials Quality Assurance Group (RTTQA), met to generate a 
unified table of normal tissue dose constraints. As a starting 
point, the UK SABR Consortium Guidelines, the AAPM TG-101 
report and other seminal publications were used to define a 
baseline reference. These initial constraints values were 
revised, where appropriate, by taking into consideration any 
updated or more robust data that better informed a given 
dose constraint value in the opinion of the panel.  
 
Results: Following an iterative process, agreement was 
reached on all dose constraints covering the central nervous 
system, thorax, abdomen, pelvis, skin and bone. It was 
agreed to use a point maximum dose volume of 0.5cc for the 
purposes of describing the maximum dose for all organs 
except the spinal cord. For the spinal cord 0.1cc is to be 
used. The group reached the consensus that for the purpose 
of these trials single fraction should not be used outside CNS. 
We recommended the use of 3, 5 and 8 fractions regimes. 
These dose constraints will be used for the forthcoming SABR 
studies and for the implementation of the CTE SABR 
programme for oligometastatic disease and HCC. The group 
will review the evidence annually to update the guidelines. 
 
Conclusion: A UK national agreement on SABR dose 
constraints has been successfully achieved. It is hoped that 
this unified approach will facilitate standardised 
implementation of SABR across the UK and will permit 
meaningful toxicity comparisons between SABR studies and 
further refinement of the constraints. Any further trials 
developed in the UK will adopt the consensus. 
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Purpose or Objective: The BSD-2000/3D system (BSD Medical 
Cooperation, Salt Lake City, USA) is used to treat deep 
seated tumors with hyperthermia (to temperatures of 41-
43°C) in combination with radiotherapy. Treatment planning 
for this system is done with the software SigmaHyperplan (Dr. 
Sennewald Medizintechnik GmbH, Munich, Germany). In this 
study a method and first results for pre-treatment 
verification of clinical patient treatment plans using a 3D SAR 
scanning phantom developed at the Kantonsspital Aarau are 
presented. 
 
Material and Methods: Treatment plans for individual 
patients were generated with SigmaHyperplan and applied to 
a saline phantom model. The result is a set of data for the 
